Pharmacokinetic drug evaluation of saxagliptin plus dapagliflozin for the treatment of type 2 diabetes

摘要: ABSTRACTIntroduction: Combining a dipeptidyl peptidase-4 inhibitor and sodium-glucose cotransporter type 2 is an attractive option to treat hyperglycaemia in diabetes.Areas covered: The saxagliptin plus dapagliflozin combination carefully analysed, focusing on: 1) pharmacokinetic properties, 2) pharmacodynamics data, 3) results of randomised controlled trials (dual versus either monotherapy, sequential therapy added or saxagliptin).Expert opinion: Pharmacokinetic findings demonstrate the absence drug-drug interaction bioequivalence FDC compared with separated tablets. Pharmacodynamic observations confirm complementary mode action two agents. Dual saxagliptin-dapagliflozin more potent than monotherapy. It may be used as initial combination, although this approach remains debatable should probably reserved case high glycated hemoglobin, stepwise strat...